ArcticZymes Technologies ASA (FRA:B4V)

Germany flag Germany · Delayed Price · Currency is EUR
1.840
+0.005 (0.27%)
Last updated: Apr 24, 2026, 8:01 AM CET
Market Cap96.90M +31.4%
Revenue (ttm)9.99M +9.3%
Net Income834.83K +16.7%
EPS0.02 +14.3%
Shares Outn/a
PE Ratio116.08
Forward PE51.46
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open1.840
Previous Close1.835
Day's Range1.840 - 1.840
52-Week Range1.240 - 2.620
Betan/a
RSI61.53
Earnings DateApr 30, 2026

About FRA:B4V

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 53
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B4V

Financial Performance

In 2025, FRA:B4V's revenue was 118.21 million, an increase of 9.34% compared to the previous year's 108.11 million. Earnings were 9.88 million, an increase of 16.66%.

Financial numbers in NOK Financial Statements